← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	2,443	+6	+0.2%	$129B
2	2 Amgen AMGN $235B	2,091	+63	+3%	$107B
3	3 Eli Lilly LLY $1.12T	1,765	+82	+5%	$122B
4	4 Becton Dickinson BDX $52.8B	1,430	+21	+1%	$59.2B
5	5 Regeneron Pharmaceuticals REGN $82B	933	+117	+14%	$57.9B
6	6 McKesson MCK $116B	864	0	0%	$22.2B
7	7 Conagra Brands CAG $6.77B	725	+52	+8%	$14.1B
8	8 AstraZeneca AZN $259B	670	+66	+11%	$22.7B
9	9 Novo Nordisk NVO $173B	661	+17	+3%	$9.36B
10	10 ResMed RMD $34.1B	583	-1	-0.2%	$19.6B
11	11 Lamb Weston LW $7.47B	574	-26	-4%	$8.39B
12	12 West Pharmaceutical WST $27B	524	+56	+12%	$15.8B
13	13 DaVita DVA $12.1B	502	+19	+4%	$9B
14	14 Teva Pharmaceutical Industries Limited TEVA $47.9B	456	-3	-0.7%	$7.14B
15	15 DELISTED CATALENT, INC. CTLT	381	+55	+17%	$11.9B
16	ARNA 16 DELISTED Arena Pharmaceuticals Inc ARNA	247	+29	+13%	$3.4B
17	17 Medifast MED $135M	224	+23	+11%	$1.69B
18	18 DELISTED WW International WW	223	+23	+12%	$1.4B
19	19 Herbalife HLF $1.53B	211	+16	+8%	$5.84B
20	20 Opko Health OPK $1.2B	210	+30	+17%	$680M
21	21 Tootsie Roll Industries TR $2.88B	205	+15	+8%	$537M
22	22 Inspire Medical Systems INSP $2.03B	189	+20	+12%	$2.35B
23	23 Accendra Health ACH $20.1M	188	+6	+3%	$429M
24	24 Fresenius Medical Care FMS $11.8B	179	+3	+2%	$404M
25	25 Dr. Reddy's Laboratories RDY $10.7B	169	+21	+14%	$1.15B